Zydus Cadila gets USFDA okay for HIV infection treatment tablets
Ahmedabad: Zydus Cadila has recently announced that the company has received final approval from the United States Food & Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg (US RLD: Truvada).
The drug is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in one's body so that the immune system can work better.
The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila seeks DCGI emergency use approval for COVID vaccine ZyCoV-D
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd